Neurogene Inc. Variable Lease, Cost
Neurogene Inc. (NGNE) reported Variable Lease, Cost of $327.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-08-11
- Neurogene Inc. variable lease, cost for the quarter ending 2026-06-30 was $327.00K, a 15.06% decline year-over-year.
- Neurogene Inc. variable lease, cost for the quarter ending 2026-03-31 was $297.00K, a 15.63% decline year-over-year.
- Neurogene Inc. variable lease, cost for the quarter ending 2025-12-31 was $386.00K, a 3.74% decline year-over-year.
- Neurogene Inc. variable lease, cost for the quarter ending 2025-09-30 was $395.00K, a 8.52% increase year-over-year.
- Neurogene Inc. variable lease, cost for fiscal 2025 was $1.52M, a 10.08% increase from fiscal 2024.
- Neurogene Inc. variable lease, cost for fiscal 2024 was $1.38M, a 674.72% increase from fiscal 2023.
- Neurogene Inc. variable lease, cost for fiscal 2023 was $178.00K, a 9.18% decline from fiscal 2022.
- Neurogene Inc. variable lease, cost for fiscal 2022 was $196.00K, a 90.93% decline from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month | Variable Lease, Cost 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $327.00K 10-Q · filed 2026-08-11 | $710.00K 10-Q · filed 2026-08-11 | $1.01M derived: sum of 3 quarters · filed 2026-08-11 | $1.41M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $297.00K 10-Q · filed 2026-05-12 | $683.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.08M derived: sum of 3 quarters · filed 2026-05-12 | $1.46M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $386.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $781.00K derived: sum of 2 quarters · filed 2026-03-24 | $1.17M derived: sum of 3 quarters · filed 2026-08-11 | $1.52M 10-K · filed 2026-03-24 | |
| 2025-09-30 | $395.00K 10-Q · filed 2025-11-13 | $780.00K derived: sum of 2 quarters · filed 2026-08-11 | $1.13M 10-Q · filed 2025-11-13 | $1.53M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $385.00K 10-Q · filed 2026-08-11 | $737.00K 10-Q · filed 2026-08-11 | $1.14M derived: sum of 3 quarters · filed 2026-08-11 | $1.50M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | $352.00K 10-Q · filed 2026-05-12 | $753.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.12M derived: sum of 3 quarters · filed 2026-05-12 | $1.40M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $765.00K derived: sum of 2 quarters · filed 2026-03-24 | $1.05M derived: sum of 3 quarters · filed 2026-03-24 | $1.38M 10-K · filed 2026-03-24 | |
| 2024-09-30 | $364.00K 10-Q · filed 2025-11-13 | $649.00K derived: sum of 2 quarters · filed 2025-11-13 | $978.00K 10-Q · filed 2025-11-13 | $1.03M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $285.00K 10-Q · filed 2025-08-11 | $614.00K 10-Q · filed 2025-08-11 | $665.00K derived: sum of 3 quarters · filed 2025-08-11 | $684.00K derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | $331.00K 10-Q · filed 2025-05-09 | $380.00K derived: sum of 2 quarters · filed 2025-05-09 | $399.00K derived: sum of 3 quarters · filed 2025-05-09 | $455.00K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $49.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $68.00K derived: sum of 2 quarters · filed 2025-03-24 | $124.00K derived: sum of 3 quarters · filed 2025-03-24 | $178.00K 10-K · filed 2025-03-24 | |
| 2023-09-30 | $19.00K 10-Q · filed 2024-11-18 | $75.00K derived: sum of 2 quarters · filed 2024-11-18 | $129.00K 10-Q · filed 2024-11-18 | ||
| 2023-06-30 | $56.00K 10-Q · filed 2024-08-09 | $110.00K 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | $54.00K 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | $196.00K 10-K · filed 2024-03-18 | $1.12M 10-K · filed 2023-03-20 | |||
| 2021-12-31 | $2.16M 10-K · filed 2023-03-20 | ||||
| 2020-12-31 | $321.00K 10-K · filed 2022-03-01 | ||||
| 2020-03-31 | $74.00K 10-Q · filed 2020-05-06 | $134.00K derived: sum of 2 quarters · filed 2021-03-25 | $165.00K derived: sum of 3 quarters · filed 2021-03-25 | $207.00K derived: sum of 4 quarters · filed 2021-03-25 | |
| 2019-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $91.00K derived: sum of 2 quarters · filed 2021-03-25 | $133.00K derived: sum of 3 quarters · filed 2021-03-25 | $181.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $31.00K 10-Q · filed 2019-11-13 | $73.00K derived: sum of 2 quarters · filed 2019-11-13 | $121.00K 10-Q · filed 2019-11-13 | ||
| 2019-06-30 | $42.00K 10-Q · filed 2019-08-01 | $90.00K 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $48.00K 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |